These scholarships, which are aimed at promoting R&D in Spain and recognizing the work of Spanish researchers, have been held for more than a decade, with an approximate investment of one million euros. Aid that is possible thanks to the collaboration between Gilead and the ISCIII, an entity that guarantees that the review process of research projects meets the principles of transparency, objectivity and independence necessary for the correct choice of projects to finance.
“It is with great satisfaction that I announce that the 11th edition of the Gilead Scholarships for Biomedical Innovation is now underway. This initiative is one of the most important of those organized in our country in the field of research, and it is a pride to see how it is consolidated and how it continues to support Spanish researchers for years. As always, the experience and good work of the Carlos III Health Institute are a guarantee of the rigor and scientific quality of the projects that will be selected,” said María Rio, vice president and general director of Gilead Spain and Portugal.
As explained Marina Pollán, director of the ISCIII, “at the Institute we find it very important to continue supporting this type of public-private collaboration initiatives, which allow us to consolidate different avenues to promote health research. As in previous years, our participation in “The evaluation of these scholarship projects represents a new example of the ISCIII’s commitment to the generation of scientific knowledge to care for people’s health.”
RECOGNITION OF EXCELLENCE
Over the years, Gilead has covered different therapeutic areas to promote research in those areas and pathologies that have urgent unmet medical needs. In this way, in this edition the best research works in HIV, covid-19, hepatitis delta, B-cell non-Hodgkin lymphomas and medical oncology will be recognized, for which there will be the collaboration of the main scientific societies and collaborative groups of these disciplines.
The evaluation of the projects will be carried out by the ISCIII, an entity that has its own experience and quality standards and the participation of national and international peer evaluators for each project.
Furthermore, in this eleventh edition, special recognition will be granted – for the fourth consecutive year – to those works presented by young researchers. An initiative with which Gilead and the ISCIII seek to highlight research work and promote the experience and talent of younger Spanish scientists in different areas with medical needs yet to be covered.
The Gilead Biomedical Research Scholarships were created in 2013 with the aim of promoting biomedical research in clinical care centers in Spain. Today they are a benchmark within the Spanish health sector, both for the investment made – around one million euros annually – and for the number of approved projects. Throughout this period, 185 projects from 13 autonomous communities have been selected.
Initiatives to apply for the Gilead Biomedical Research Scholarships must be submitted in English until Sunday, June 30, on the website ‘https://becasgileadinvestigacion.es/’. Each principal investigator may only present one research project and a maximum of two projects will be allowed per therapeutic area and health care center to which the principal investigator (PI) is assigned. Subsequently, the Carlos III Health Institute will be in charge of reviewing the projects and preparing the priority list.
